# Maura N. Dickler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maura-n-dickler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,923 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 58 |
| i10-index | 124 |
| OpenAlex ID | https://openalex.org/A5069795948 |
| ORCID iD | 0000-0003-4631-6572 |
| Works | 359 |

## Researcher papers

- [Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer](https://scholariq.org/papers/paclitaxel-plus-bevacizumab-versus-paclitaxel-alone-for-metastatic-breast-cancer/)
- [Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-trial-of-capecitabine-compared-with-bevacizumab-plus/)
- [The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers](https://scholariq.org/papers/the-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline](https://scholariq.org/papers/endocrine-therapy-for-hormone-receptor-positive-metastatic-breast-cancer/)
- [Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100](https://scholariq.org/papers/association-of-vascular-endothelial-growth-factor-and-vascular-endothelial/)
- [Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by <i>HER2</i> Immunophenotype and Gene Amplification](https://scholariq.org/papers/weekly-trastuzumab-and-paclitaxel-therapy-for-metastatic-breast-cancer-with/)
- [Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing](https://scholariq.org/papers/mutation-detection-in-patients-with-advanced-cancer-by-universal-sequencing-of/)
- [Impairment of BRCA1-Related DNA Double-Strand Break Repair Leads to Ovarian Aging in Mice and Humans](https://scholariq.org/papers/impairment-of-brca1-related-dna-double-strand-break-repair-leads-to-ovarian/)
- [PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer](https://scholariq.org/papers/pi3k-inhibition-results-in-enhanced-estrogen-receptor-function-and-dependence-in/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up](https://scholariq.org/papers/breast-carcinoma-with-21-gene-recurrence-score-lower-than-18-rate-of/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.